title: [Effect of S-1 in a patient with metastatic eyelid sebaceous carcinoma].
abstract: We report a 68-year-old female with a history of repeated right cervical lymph node metastasis secondary to eyelid sebaceous carcinoma. She had undergone right neck dissection due to lymph node metastasis at the department of surgery in an other local hospital. After the orbital exenteration, she underwent multiple operations, including 2 right partial parotidectomy and then total parotidectomy, 4 right cervical lymph node excisions and 1 left upper neck dissection due to lymph node metastasis. Adjuvant chemotherapy with S-1(at a dose of 80 mg per day)alone was applied as tumor dormancy therapy on an outpatient basis. Any adverse events during S-1 medication were observed. New metastatic lesions were not found until 29 months after the beginning of chemotherapy with S-1 alone. Although the effectiveness of S-1 for eyelid sebaceous carcinoma has not been demonstrated, S-1 might be useful in patients with recurrent eyelid sebaceous carcinoma based on our patient's recurrence-free survival.
authors.affiliation: Dept. of Otorhinolaryngology, Head and Neck Surgery, University of Toyama.
authors.forename: Satsuki
authors.initials: S
authors.lastname: Yasumura
authors.forename: Hideo
authors.initials: H
authors.lastname: Shojaku
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Takakura
authors.forename: Michiro
authors.initials: M
authors.lastname: Fujisaka
authors.forename: Masahito
authors.initials: M
authors.lastname: Tsubota
authors.forename: Akira
authors.initials: A
authors.lastname: Naruse
authors.forename: Hirohiko
authors.initials: H
authors.lastname: Tachino
authors.forename: Motoyoshi
authors.initials: M
authors.lastname: Maruyama
authors.forename: Yukio
authors.initials: Y
authors.lastname: Watanabe
mesh_terms: D000368:Aged; D004338:Drug Combinations; D005142:Eyelid Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D010094:Oxonic Acid / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D012626:Sebaceous Gland Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid